KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查 入排置信度 0.90

Quality of life in patients with locally advanced head and neck squamous cell carcinoma undergoing concurrent chemoradiation with once-a-week versus once-every-3-weeks cisplatin.

Nandini S Menon, Vanita Noronha, Vijay Maruti Patil, Amit Joshi, Atanu Bhattacharjee, Devanshi Kalra, Sarbani Ghosh Laskar, Vijayalakshmi Mathrudev, Kavita Nawale, Arati S Bhelekar, Kumar Prabhash

Cancer Med 11(21) 3939-3948

PMID35343648
PMCIDPMC9636500
DOI10.1002/cam4.4715
发表日期2022-03-28
入排依据:The record is a Phase III randomized trial of a drug-containing intervention in oncology, but the abstract explicitly states the primary endpoint was locoregional control and the focus of this report is the key secondary endpoint of quality of life. It does not report a primary or key secondary time-to-event efficacy endpoint (such as OS, PFS, DFS, etc.) with Kaplan-Meier or HR results. Therefore, it is excluded based on the time_to_event criterion.
摘要

摘要

INTRODUCTION: This trial was conducted to compare the efficacy of low dose once-a-week cisplatin and once-every-3-weeks cisplatin with radiation in locally advanced head and neck squamous cell carcinoma (LAHNSCC). The current analysis focuses on the quality of life (QoL) of patients in this trial. METHODS: In this phase III randomized trial, patients with nonmetastatic LAHNSCC were randomized to receive cisplatin 30 mg/m2 once-a-week or 100 mg/m2 once every- 3-weeks concurrently with radiotherapy. The primary endpoint was locoregional control. QoL was a key secondary endpoint. QoL was assessed using EORTC QLQ-C30 and QLQ-H&N35. QoL data were assessed at baseline, days 22 and 43 during treatment; and at 6, 12, 24 months. The linear mixed-effects model was used for longitudinal analysis of QoL to determine the impact of treatment (arm) and time on QoL. RESULTS: Three hundred patients were enrolled, data of 150 patients with available baseline QoL were analyzed. There was no significant difference in the global health status/QoL of the two treatment arms (p = 0.8664). There was no significant difference in the longitudinal QoL scores between the two treatment arms in all scales except constipation (p = 0.0096), less sexuality (p = 0.0002,), and financial difficulty (p = 0.0219). There was a worsening of the QoL scores in all scales in both arms during treatment, which improved after treatment completion in most scales. CONCLUSION: The use of once-every-3-weeks cisplatin did not adversely impact QoL as compared to once-a-week cisplatin in combination with radiotherapy in LAHNSCC.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。